The use of allele-specific quantitative polymerase chain reaction to identify KIT D816V in the peripheral blood of adults with mastocytosis has been reported to have value in the diagnosis, assessment of disease burden and management of this disease. To examine the value of this assay in children with cutaneous manifestations of mastocytosis, we assessed data on 65 patients with all variants of paediatric-onset mastocytosis, including those known to have systemic disease, to correlate KIT mutation status with clinical findings, serum tryptase levels and bone marrow histopathology. We found that KIT D816V was not identified in the peripheral blood of children known to have only cutaneous disease (specificity 100%) but was found in those known to have both cutaneous and systemic/probable systemic disease (sensitivity of 85Á2%). These findings were the basis of the development of an algorithm to assist in the decision for when to perform a bone marrow biopsy in children presenting with cutaneous manifestations of mastocytosis.
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Mastocytosis is a clonal mast cell disease characterized by the presence of elevated or excessive numbers of mast cells in the skin and internal organs, such as the bone marrow, gastrointestinal tract, lymph nodes, liver and spleen (Valent et al, 2001) . Symptoms related to mast cell degranulation are frequently observed in all categories of mastocytosis. Mastocytosis may present with varied clinical manifestations depending on the mast cell burden and the extent of tissue involvement. Children are primarily represented on the benign end of the disease spectrum, with disease limited to skin and diagnosed with one of three cutaneous variants; maculopapular cutaneous mastocytosis (MPCM), diffuse cutaneous mastocytosis (DCM) or mastocytoma (MTOMA) (Valent et al, 2017) . Systemic mastocytosis is typically seen in adults with somatic mutations in KIT. However, children may also have systemic disease, with similar mutations in KIT and as early as infancy (Carter & Metcalfe, 2002; Castells et al, 2011; Hartmann et al, 2016) .
There are several published algorithms to assist in the diagnostic approach and determine which adults are more likely to have systemic disease (Alvarez-Twose et al, 2010; Gulen et al, 2014; Carter et al, 2018) . Recent studies identifying and quantitating the KIT D816V mutation in peripheral blood (PB) in adults have suggested it to be a valuable tool for diagnosis, (Kristensen et al, 2011 (Kristensen et al, , 2014 Jara-Acevedo et al, 2015) to determine disease burden and monitoring (Erben et al, 2014) , and to assess response to therapy (Hoermann et al, 2014) . In adults, the KIT D816V allelic burden in PB correlates with serum tryptase (Kristensen et al, 2013; Erben et al, 2014; Hoermann et al, 2014) . However, the diagnosis of systemic disease in children remains a challenge because, outside of the clinical finding of organomegaly, which correlates with systemic disease, surrogate markers to help identify those children where a marrow examination might be warranted to establish systemic disease, are lacking (Carter et al, 2015) .
Because of the value of allele-specific quantitative polymerase chain reaction (ASqPCR) to identify KIT D816V in the PB of adults, we examined the value of this test in determining systemic disease in children known to have cutaneous mastocytosis (CM) and in children known to have both cutaneous and systemic disease. We also investigated whether results obtained with this technique would correlate with the degree of severity of systemic disease. As will be shown, ASqPCR to identify KIT D816V in the PB of children has value in identifying children with systemic disease, while correlating with serum tryptase, disease variant and disease severity.
Methods

Patients
Sixty-five paediatric patients diagnosed with CM, some of whom were subsequently diagnosed with systemic disease, were consented and enrolled in an Institutional Review Board-approved National Institutes of Health protocol (NCT00044122). The male/female ratio was 33/32 and 93Á8% of the patients were Caucasian. In addition to an evaluation that included routine laboratory studies, determination of serum tryptase levels and bone marrow procedures when clinically indicated, PB was analysed for the KIT D816V mutation (Kristensen et al, 2011 (Kristensen et al, , 2014 . Within this group of children, 25 carried the diagnosis of MPCM (38Á5%), 10 had DCM (15Á4%), 2 had MTOMAs (3Á0%), 5 with probable indolent systemic mastocytosis (pISM, 7Á7%) and 23 were diagnosed with cutaneous disease along with indolent systemic mastocytosis (ISM, 35Á4%) ( Table I ). All children with a diagnosis of systemic disease had a bone marrow procedure and met criteria for the diagnosis of ISM by World Health Organization (WHO) criteria (Valent et al, 2017) . The bone marrow procedure was performed with anaesthesia-monitored assistance for safety and comfort without any adverse events. Five patients had laboratory and clinical data, including organomegaly, that supported the diagnosis of ISM but had not undergone a bone marrow biopsy at the time of this report and are categorized as pISM.
Serum tryptase
Serum tryptase levels were determined using the commercial fluoroenzyme immunoassay (Phadia Immuno CAP, Uppsala, Sweden) at Clinical Laboratory Improvement Amendments (CLIA)-approved laboratories. The normal reference range for this assay is 0Á00-11Á50 ng/ml (Table I) .
Bone marrow preparation and flow cytometry
Bone marrow aspirates and biopsies were processed and stained according to standard protocols as described (Maric et al, 2007) . Multi-parameter flow cytometry was performed on aspirates for CD2, CD25, CD45 and CD117. The CellQuest program was used for data analysis (Maric et al, 2007) .
KIT D816V mutational analysis KIT D816V allele burden was quantified from the genomic DNA from PB using ASqPCR, as previously described in detail (Kristensen et al, 2011) . The assay is considered positive with values of ≥0Á01%. Detection of the KIT D816V mutation in bone marrow aspirates was performed prospectively by reverse transcription (RT)-PCR/restriction fragment length polymorphism (RFLP) assay in 23 samples as described (Maric et al, 2007) on samples collected prior to 2014, and samples collected after 2014 were prospectively analysed by ASqPCR. KIT D816V ASqPCR from the genomic DNA was used to retrospectively analyse 20 bone marrow aspirates frozen in liquid nitrogen.
Statistical analysis
We compared the differences in the percentage of KIT D816V allele burden in both PB and bone marrow aspirate, using the Kruskal-Wallis non-parametric statistical test given the non-Gaussian distribution of our data. Two-tailed P values <0Á05 were considered statistically significant. Correlations are represented by the Spearman's correlation coefficient (r s ), including the 95% confidence interval (CI). For graphical representation purposes, 0Á001 was chosen as our zero-value. Statistical analysis was performed using GraphPad PRISM 6.0 software (GraphPad Software Inc., La Jolla, CA, USA). Sensitivity and specificity data were calculated using standard statistical models.
Results
The PB ASqPCR for the KIT D816V mutation was consistently negative in patients with cutaneous disease only (MCPM, DCM and MTOMA, n = 37) and without a history of organomegaly documented to be associated with systemic disease in paediatric patients (Table II) (Carter et al, 2015) . Of the 23 patients diagnosed with systemic disease (ISM), the PB ASqPCR was positive in 16/23 samples (0Á047-38Á4%). PB ASqPCR was negative in two ISM patients with organomegaly that had KIT D816Y-associated systemic disease (serum tryptase values 184 and 244 ng/ml), one patient with a bone marrow diagnosis of ISM and no KIT mutations detected in the marrow samples, as well as four patients diagnosed with ISM by bone marrow biopsy. These latter four patients had a low mast cell disease burden in bone marrow biopsies (mast cells ≤ 5% of total marrow cells); but positive KIT D816V mutation by RT-PCR/RFLP in their marrow samples. As PB ASqPCR for the KIT D816V mutation was not performed at the time of the original bone marrow biopsy procedure in these four patients, we obtained their frozen PB samples collected at the time of the bone marrow biopsy procedure and analysed them using ASqPCR for the KIT D816V mutation. The results were negative in all four samples. In addition, there has been a significant improvement in their clinical status, as evidenced by a major or complete resolution of skin lesions, a significant decrease in serum tryptase (average 33Á9 to 11Á0 ng/ml) and a decrease in medication usage to as needed medications from daily dosing over a period of 7-13 years (Data not shown). Our cohort contained five patients with a probable diagnosis of ISM because of the clinical findings and the presence of organomegaly; however, none of these patients have had a bone marrow biopsy to confirm diagnosis of systemic mastocytosis. All five patients had positive results using the PB ASqPCR KIT D816V assay (range 0Á03-12Á70%) (Fig 1) . These patients also had an elevated serum tryptase (range 20Á8-38Á2 ng/ml). The ASqPCR for KIT D816V in PB significantly correlated with the serum tryptase (Fig 2) (r 2 = 0Á49, P = 0Á006), similar to findings in studies of adults with ISM (Kristensen et al, 2013) . In most patients, the ASqPCR value also correlated with clinical symptoms. The specificity of PB ASqPCR KIT D816V assay was 100% for all variants of cutaneous disease. The sensitivity for the detection of the systemic disease when documented with a marrow biopsy, was 69Á6% (Table II) and was 85Á2% when results were combined for pISM and ISM. The total population sensitivity and specificity, including patients with ISM diagnosed by bone marrow biopsy plus pISM patients was 75Á0% and 100Á0%, respectively (Table II) . When considering patients with cutaneous and systemic disease who underwent a bone marrow procedure and had a positive ASqPCR in marrow, the results for the PB KIT D816V mutation had a sensitivity and specificity of 80% and 100%, respectively (Table III) . The positive predictive value (PPV) and negative predictive value (NPV) for the total group was 100% (83Á9, *ISM with KIT D816Y mutation (n = 2) and ISM-negative for PB KIT D816V (n = 5). Peripheral blood allele-specific quantitative polymerase chain reaction for KIT D816V was consistently negative in the cutaneous variants and negative in patients with KIT D816Y, as shown. Patients with ISM and a low allelic burden were also negative in the assay. Negative values are charted as 0Á001 for graphical presentation. DCM, diffuse cutaneous mastocytosis; ISM, indolent systemic mastocytosis; MPCM, maculopapular cutaneous mastocytosis; pISM, probable ISM. 100) and 84Á1% (69Á9, 93Á3), respectively. The PPV and NPV for the subgroups are 100%, by definition.
We performed follow-up PB ASqPCR testing in most patients (61Á5%). Data was found to yield consistent results when followed up to 36 months. Patients with a positive value remained positive (Fig 3) and these results continued to correlate with serum tryptase values (data not shown). In addition, the patients with negative values remained negative.
We also compared the results of the KIT D816V analysis of the bone marrow compartment to verify correlations, as seen in adult patients with systemic disease (Jara-Acevedo et al, 2015) and found similar correlations in the paediatric cohort. Thus, in patients with both cutaneous and systemic disease, the KIT PB ASqPCR results correlated with the bone marrow ASqPCR results (Fig 4A) . In addition, the bone marrow KIT ASqPCR results correlated with the serum tryptase as well as the bone marrow mast cell burden (Fig 4B, C) .
Finally, we used clinical and laboratory data to construct an algorithm to assist in the evaluation of paediatric patients diagnosed with CM to determine who might have a high probability of systemic disease and thus be candidates for a marrow biopsy (Fig 5) . The algorithm focuses on children with CM, as paediatric patients without cutaneous disease are far less likely to have systemic disease compared to adults (Valent et al, 2001 (Valent et al, , 2007 Sperr et al, 2002; Florian et al, 2005) . Recommendations for monitoring are included in the discussion. This data also suggests that in patients with a high suspicion of systemic mastocytosis, one should pursue a more extensive approach and assay for other KIT mutations, as well as entertain a bone marrow procedure if other therapeutic options need to be considered (Fig 5) .
Discussion
We have examined the value of PB ASqPCR for the identification of the KIT D816V mutation in the diagnosis and management of children with paediatric mastocytosis. The decision of when to perform a bone marrow in children with CM can be difficult. Although none of the bone marrow procedures reported in our paper were associated with an adverse event, the adverse events reported to be associated with a bone marrow biopsy and aspirate in children include haemorrhage, infection and persistent pain at the marrow site (in total 0Á08%) (Abla et al, 2008) . Our data expands our previous report recommending an abdominal ultrasound if organomegaly is suspected (Carter et al, 2015) and further supports a conservative approach using the combination of clinical and laboratory data to determine when a child should be considered for a bone marrow procedure. In addition, this data supports the use of PB ASqPCR to follow disease status in children over time and to assist in determining if a more aggressive approach is needed for disease management, but also supports long-term follow-up with PB assays.
Patients with cutaneous variants of CM (MPCM, MTOMA, DCM) without other parameters of systemic disease, such as organomegaly, had consistently negative PB ASqPCR for KIT D816V. We have found the data to be consistent and reliable when positively correlated with systemic disease. We are always exploring options to minimize invasive procedures in children. This is particularly important in infants and toddlers. We have implemented this protocol in our patient population and currently using it to monitor patients with systemic disease and delay a bone marrow ASqPCR, allele-specific quantitative polymerase chain reaction; BM, bone marrow; CI, confidence interval; DCM, diffuse cutaneous mastocytosis; ISM, indolent systemic mastocytosis; MPCM, maculopapular cutaneous mastocytosis; MTOMA, mastocytoma; PB, peripheral blood; pISM, patients with probable ISM diagnosed based on PB KIT D816V mutation and organomegaly, bone marrow not yet done.
procedure in younger patients with a positive PB assay, and support the diagnosis of CM in patients with an elevated serum tryptase without other clinical parameters of systemic disease.
A recent prospective study in adult patients reports the PB ASqPCR assay as a reliable predictor of systemic mastocytosis without false positive results. This study also reports a negative PB KIT D816V mutational analysis in patients with positive bone marrow results in patients with a low mast cell burden (Kristensen et al, 2017) . We found comparable results in our paediatric population, as shown in four patients with documented systemic mastocytosis and a low bone marrow mast cell burden and who only met minor WHO criteria for the diagnosis. These patients also had relatively low serum tryptase levels (all <20 ng/ml) at the time when the PB ASqPCR assay was negative. We have reported a similar observation in adult patients with idiopathic anaphylaxis with isolated bone marrow mastocytosis (Carter et al, 2015 (Carter et al, , 2018 , which is supported by other reports (Erben et al, 2014; Kristensen et al, 2014 Kristensen et al, , 2017 Carter et al, 2018) . This is consistent with the low frequency of cells bearing the mutated allele in patients with minimal disease or improving clinical status.
The outcome of sequencing KIT in skin in children with CM may vary from our study, which relied on correlating data with documented evidence of systemic disease. In one study (Bodemer et al, 2010) , KIT was sequenced in the skin of 50 children. Forty-two percent had a KIT mutation at codon 816, 44% had mutations at other locations in KIT and no KIT mutations were found in 14%. However, no bone marrow biopsies to document systemic disease were performed, so the relationship to systemic disease or any of these mutations was not determined. However, in our study, bone marrow examinations were performed in all patients with suspected systemic disease. Here we found that mutations at codon 816 occurred in 96% of those with systemic disease. One interpretation of this data from the two studies is that systemic disease in children is rarely associated with mutations in KIT outside of codon 816. We recognize that mutations may be found in skin not associated with systemic disease and this is of interest in exploring the basis of skin lesions, particularly if transient. Our algorithm (Fig 5) will help guide clinicians in the management of paediatric patients with mastocytosis. Cutaneous lesions are typical for paediatric disease and, unlike adults with systemic disease, children rarely present with systemic disease without current cutaneous lesions or a history of CM (Muller et al, 1990; Ben-Amitai et al, 2005; Lange et al, 2013) . However, should a child without CM present with other findings that suggest the possibility of systemic mastocytosis, such as severe episodes of mediator release, an elevated tryptase and/or organomegaly, we would recommend that ASqPCR be performed on PB in the diagnostic workup. The proposed algorithm starts with clinical parameters with and without organomegaly. The ASqPCR assay adds a surrogate marker of the presence of an expanding mast cell clone. If positive, it helps physicians and parents decide the appropriate situation for a bone marrow procedure. In addition, it may confirm the suspicion of a mast cell disorder in a patient with organomegaly and allay the anxiety associated with an elevated serum tryptase in patients without the other clinical parameters when the assay is negative. Given that our data has shown consistent results for the assay over several years (Fig 3) , the algorithm recommends using the assay to follow disease annually. A principle concern of parents is the long-term prognosis of mastocytosis. The annual review supports the parents and patients with a clinical assessment and objective assays, such as serum tryptase and ASqPCR, for signs of progression and appropriate therapeutic intervention.
The PB ASqPCR for KIT D816V is available commercially for use as a screening test for the consideration of systemic disease (Erben et al, 2014; Kristensen et al, 2017) . Therapeutic management is symptom-based and only in unusual cases would children require cytoreductive therapy that would be guided by the KIT mutational status. Therefore, the timing of a bone marrow procedure in children is flexible and depends on concern over the severity of the clinical status.
As we documented in a previous studies, children with mastocytosis tend to improve over time and this resolution Algorithm for utilization of ASqPCR for diagnosis and management. Children diagnosed with cutaneous manifestations of mastocytosis without other clinical parameters such as organomegaly rarely are diagnosed with indolent systemic mastocytosis. PB ASqPCR is helpful to distinguish those patients for whom a bone marrow procedure should be considered. A positive value correlates with systemic disease. A negative value in patients with organomegaly and an elevated serum tryptase may indicate a low allelic burden. These patients may be followed annually to monitor their disease burden. ASqPCR, allele-specific quantitative polymerase chain reaction; BM, bone marrow; MC, mast cell; PB, peripheral blood; SM, systemic mastocytosis.
correlates with serum tryptase levels (Middelkamp Hup et al, 2002; Carter et al, 2015) . Four patients with a bone marrowconfirmed diagnosis of systemic disease with a low mast cell burden, resolution of splenomegaly and a decreasing serum tryptase value over time, had negative ASqPCR values. Thus, the assay supported major disease resolution as documented in our prior publications (Ben-Amitai et al, 2005; Lange et al, 2013; Carter et al, 2015) , with cessation of a need for daily medication, major clearing of skin lesions and a significant decrease in serum tryptase, which is an indication of mast cell burden. Together with clinical parameters, PB ASqPCR may also be employed to follow disease progression or resolution. Our results show that the use of PB ASqPCR assay in conjunction with additional clinical parameters for systemic disease, such as organomegaly (Carter et al, 2015) , is extremely useful in identifying children with a high probability of systemic disease; thus, avoiding an unnecessary bone marrow procedure in those unlikely to have systemic disease.
This study thus expands our armamentarium for the comprehensive care of children with mastocytosis.
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